Section Arrow
INAB.NASDAQ
- IN8bio Inc
Quotes are at least 15-min delayed:2026/04/17 04:20 EDT
Pre Market
Last
 1.4
-0.05 (-3.45%)
Bid
1.4
Ask
1.65
High 1.45 
Low 1.4 
Volume 46 
Regular Hours (Closed)
Last
 1.45
+0.05 (+3.57%)
Day High 
1.48 
Prev. Close
1.4 
1-M High
2.11 
Volume 
89.87K 
Bid
1.4
Ask
1.65
Day Low
1.3688 
Open
1.42 
1-M Low
1.31 
Market Cap 
13.79M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.41 
20-SMA 1.51 
50-SMA 1.68 
52-W High 5.817 
52-W Low 1.17 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.44/-1.68
Enterprise Value
15.35M
Balance Sheet
Book Value Per Share
2.80
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PBMPsyence Biomedical Ltd.5.87+2.99+103.82%-- 
Pre Market 11.63 +5.76 +98.13%
IMMPImmutep Limited0.5796+0.0356+6.54%-- 
Pre Market 0.5433 -0.0363 -6.26%
ALLOAllogene Therapeutics2.37+0.2+9.22%-- 
Pre Market 2.3742 +0.0042 +0.18%
ASBPAspire Biopharma Holdings Inc.0.3-0.2449-44.94%-- 
Pre Market 0.3 0 0.00%
IBRXImmunityBio7.25-0.53-6.81%-- 
Pre Market 7.27 +0.02 +0.28%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.